Patents Issued in September 20, 2018
  • Publication number: 20180267018
    Abstract: The present invention provides biomarkers and a method for diagnosing a liver disease in a subject such as steatosis, inflammatory liver disease, NASH, and NAFLD. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.
    Type: Application
    Filed: May 18, 2018
    Publication date: September 20, 2018
    Applicants: METANOMICS HEALTH GMBH, Universitätsklinikum Schleswig-Holstein
    Inventors: Hennicke Kamp, Ulrike Rennefahrt, Jens Fuhrmann, Dietrich Rein, Jochen Hampe, Clemens Schafmayer
  • Publication number: 20180267019
    Abstract: An assay mixture includes a hydrogel of a shear-thinning ?-hairpin peptide, a plurality of cells, and one or more predetermined compounds being investigated for ability to affect the growth, viability, reproduction characteristics, or activity of the cells. A high throughput screening device includes a plurality of sample wells adapted for high throughput screening, wherein each well contains the assay mixture. A method of using the high throughput screening device includes a) depositing in each of the wells a ?-hairpin hydrogel including the cells; depositing in at least some of the wells one or more of the compounds, either along with the ?-hairpin hydrogel or separately; and c) measuring the growth, viability, reproduction characteristics, or activity of the cells in each of the plurality of wells.
    Type: Application
    Filed: September 23, 2016
    Publication date: September 20, 2018
    Applicants: UNIVERSITY OF DELAWARE, THE NEMOURS FOUNDATION
    Inventors: Sigrid A. LANGHANS, Darrin J. POCHAN, Peter WORTHINGTON, Andrew D. NAPPER
  • Publication number: 20180267020
    Abstract: Provided herein are methods of diagnosing and/or treating ACVS, by determining expression levels of several ACVS-related molecules, such as FABP3, ANPR-1, IGFBP-3, F9, SELL, apoB100, ADPN, vWF, THBS1, PRL, PON3, EGFR, VEGF-D, HPX, MBT, F5, F10, SERPIN A5, HCII, and HABP2, for example in a blood sample.
    Type: Application
    Filed: March 19, 2018
    Publication date: September 20, 2018
    Applicants: UVic Industry Partnerships Inc., Vancouver Island Health Authority, British Columbia Center for Disease Control, The Governors of the University of Calgary
    Inventors: Andrew Penn, Christoph Hermann Borchers, Mary Louise Lesperance, Angela Marie Jackson, Maximilian Barnaby Bibok, Viera Saly, Robert Fred Balshaw, Shelagh Brown Coutts
  • Publication number: 20180267021
    Abstract: The invention in some aspects relates to high throughput methods and devices for evaluating mechanical, morphological, kinetic, rheological or hematological properties of cells, such as blood cells under regulated gas conditions. In some aspects, the invention relates to methods and devices for diagnosing and/or characterizing a condition or disease in a subject by measuring a property of a cell from the subject, under controlled gas conditions.
    Type: Application
    Filed: December 4, 2015
    Publication date: September 20, 2018
    Applicants: Carnegie Mellon University, Massachusetts Institute of Technology
    Inventors: Subra SURESH, E. DU, Monica DIEZ SILVA, Ming DAO
  • Publication number: 20180267022
    Abstract: In one aspect of the present specification, provided is a method for predicting a side effect of a whitening ingredient, the method comprising measuring at least one of i) the increase in toxicity according to long-term use of a whitening ingredient, ii) the difference between a concentration having whitening effect and a concentration having cell toxicity, and iii) the increase in sensitivity to the whitening ingredient according to ultraviolet pretreatment. In addition, the method has an effect of effectively predicting whether a side effect will occur if the whitening ingredient is used for a long time.
    Type: Application
    Filed: February 26, 2016
    Publication date: September 20, 2018
    Inventors: Chang Seok LEE, Heung Soo BAEK, Yung Hyup JOO, Jeong Hwan KIM, Hong-Ju SHIN, Mi Young PARK, Song Seok SHIN
  • Publication number: 20180267023
    Abstract: A method for evaluating in vitro the effect of a xenobiotic (e.g., a drug) on drug metabolism in hepatocytes. The kit comprises a first culture of hepatocytes, a portion of in vitro xenobiotic-stimulated biological sample, and instructions for incubating the first culture of hepatocytes with the portion of in vitro xenobiotic-stimulated biological sample, and analyzing the activity, expression, or a combination thereof of a biomarker in the hepatocytes to evaluate the effect of the xenobiotic on drug metabolism in the hepatocytes.
    Type: Application
    Filed: May 18, 2018
    Publication date: September 20, 2018
    Inventors: Maciej Czerwinski, David Benjamin Buckley, Faraz Kazmi
  • Publication number: 20180267024
    Abstract: The present invention relates to a composition comprising (i) a first substance which is capable to stimulate T cells, (ii) a second substance which is capable to stimulate NK cells (natural killer cells), and (iii) lipopolysaccharide (LPS) and wherein the second substance is a double stranded nucleic acid, single stranded nucleic acid, unmethylated CpG oligodeoxynucleotide, TLR agonist except lipopolysaccharide (LPS), arabinoxylan (BioBran® MGN-3), an immunoglobulin, a murine cytomegalovirus (MCMV)-encoded protein, CCL5 (chemokine (C—C motif) ligand 5), a UL-16-binding protein (ULBP), CD48, CD70, CD155, CD112, Necl-1, B7-H6, ICAM-1, RAE-1 (retinoic acid early inducible 1), H60, Mult1 and/or hemagglutinin, to a method for measuring, determining and/or detecting the status of cell-mediated immune responsiveness of a subject, to a kit comprising the composition according to the invention, to the use of the composition for measuring, determining and/or detecting of cell-mediated immunity (CMI) and/or for detecti
    Type: Application
    Filed: June 8, 2016
    Publication date: September 20, 2018
    Inventors: Ludwig DEML, Sascha BARABAS, Mathias SCHEMMERER
  • Publication number: 20180267025
    Abstract: The invention provides for detecting target subpopulations of cells that have high proliferative and renewal properties in animals, including circulating tumor cells, cancer stem cells, hematopoietic stem cells and endothelial progenitor cells. The invention utilizes a defined substrate and media of known property to enrich target cell subpopulations which can be used for future genetic, proteomic and morphological analyses. The method can use image-capture and analysis software to characterize cells based on physical properties, such as size, morphology and kinetic properties.
    Type: Application
    Filed: November 20, 2017
    Publication date: September 20, 2018
    Inventor: James LIM
  • Publication number: 20180267026
    Abstract: A method for manufacturing a measuring kit is disclosed. The method for manufacturing a measuring kit includes steps of providing a carrier including a substrate having a surface; coating a silane onto the surface of the substrate; providing an organic molecule; adding the organic molecule onto the carrier; outputting a microwave energy by a coaxial cable; and emitting the microwave energy through a radiator to microwave the carrier and the organic molecule uniformly to coat the organic molecule onto the carrier carrying the silane, wherein the measuring kit is used to apply an enzyme-linked immunosorbent assay.
    Type: Application
    Filed: March 13, 2018
    Publication date: September 20, 2018
    Inventors: Chuen-Yuan Hsu, Yi-Heui Hsieh, Chiao-Wen Huang
  • Publication number: 20180267027
    Abstract: A single stranded nucleic acid biosensor for S-adenosylhomocysteine (SAH) is provided. The single stranded nucleic acid may include a SAH-binding riboswitch domain comprising a P2? stem and a contiguous Spinach aptamer domain terminated at a P2 stem that is operably connected to the P2? stem of the SAH-binding riboswitch domain via a P2/P2? stem comprising 5 base pairs or less. The SAH biosensor may further include a signaling chromophore specifically bound to the Spinach aptamer domain, where the sensor is configured to fluorescently activate the signaling chromophore upon specific binding of SAH to the SAH-binding riboswitch domain. Also provided are methods in which the subject SAH biosensors fmd use including methods for determining the level of SAH in a sample and methods for determining the level of methyltransferase activity in a cell. Nucleic acid constructs for the single stranded nucleic acid and host cells including the same are also provided.
    Type: Application
    Filed: October 25, 2016
    Publication date: September 20, 2018
    Inventors: Ming Hammond, Yichi Su, Scott F. Hickey, Samantha G.L. Keyser
  • Publication number: 20180267028
    Abstract: The present invention provides small molecule compounds that can form covalent adducts with specific sequences of RNA, such as the hairpin loop r(CUG)exp sequence which is a cause of myotonic dystrophy type 1 (DM1), or the r(CGG)exp sequence which is a cause of fragile X-associated tremor/ataxia syndrome (FXTAS); to methods of making the small molecule compounds; and to methods of using the small molecular compounds in the treatment of DM1 or of FXTAS in patients afflicted therewith. The invention further provides a method for identifying an RNA target of a small molecule drug in vivo, using a small molecule drug conjugated to an RNA-reactive crosslinker group and a reporter group, contacting a cell or nucleic acid extract with the small molecule drug conjugate, then separating RNA targets crosslinked to the small molecule drug conjugate by interaction of the affinity group with a complementary affinity group.
    Type: Application
    Filed: March 8, 2018
    Publication date: September 20, 2018
    Inventors: Matthew D. Disney, Lirui Guan, Wang-Yong Yang
  • Publication number: 20180267029
    Abstract: Biomolecule arrays on a substrate are described which contain a plurality of biomolecules, such as coding nucleic acids and/or isolated polypeptides, at a plurality of discrete, isolated, locations. The arrays can be used, for example, in high throughput genomics and proteomics for specific uses including, but not limited molecular diagnostics for early detection, diagnosis, treatment, prognosis, monitoring clinical response, and protein crystallography.
    Type: Application
    Filed: March 28, 2018
    Publication date: September 20, 2018
    Inventors: Peter Wiktor, Joshua Labaer, Peter Kahn, Bharath Takulapalli, Ji Qiu, Al Brunner, Mitch Magee
  • Publication number: 20180267030
    Abstract: Seroprotection analysis systems, kits, and techniques are described for testing oral fluid for the presence of protective levels of antibodies of interest. In one aspect, the presence of protective levels of target antibodies indicates a test subject has achieved a target seroprotection level, such as but not limited to a target seroprotection level following vaccination. A collection kit can include a swab that enables collection of oral fluid containing antibodies from both dentulous and edentulous individuals, a container that can be pre-filled with an extraction solution, and a nozzle that can be coupled to the container to form a fluid-tight device. A user can use the nozzle to seal the swab in the container and to compress the swab within the container.
    Type: Application
    Filed: March 13, 2018
    Publication date: September 20, 2018
    Applicants: Becton, Dickinson and Company, University of Maryland, Baltimore
    Inventors: Michael D. Fiechtner, Francis R. Go, Myron Levine, Scott Castanon
  • Publication number: 20180267031
    Abstract: Methods for detecting antigen-specific antibodies in a biological sample are described. The disclosed methods can be used for the diagnosis of a variety of autoimmune and infectious diseases. The methods use a neodymium magnet to efficiently isolate immune complexes. The disclosed methods are rapid, highly specific and sensitive, require very small volumes of biological sample, and do not require the use of radioactivity. With these advantageous features, the disclosed methods are amendable for point-of-care testing (POCT), which is currently not available for the detection of autoantibodies associated with autoimmune disease or for the detection of many pathogen-specific antibodies.
    Type: Application
    Filed: August 8, 2016
    Publication date: September 20, 2018
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventor: Peter D. Burbelo
  • Publication number: 20180267032
    Abstract: There is disclosed a microarray having base cleavable linkers and a process of making the microarray. The microarray has a solid surface with known locations, each having reactive hydroxyl groups. The density of the known locations is greater than approximately 100 locations per square centimeter. Optionally, oligomers are synthesized in situ onto the cleavable linkers and subsequently cleaved using a cleaving base. Optionally, the oligomers are cleaved and recovered as a pool of oligomers.
    Type: Application
    Filed: May 25, 2018
    Publication date: September 20, 2018
    Applicant: CustomArray, Inc.
    Inventors: Karl Maurer, Dominic Suciu, Hetian Gao
  • Publication number: 20180267033
    Abstract: A problem to be solved by the present invention is to provide an immunochromatographic test strip and a detection method using immunochromatography avoiding aggregation of colloidal gold conjugates while red blood cells in whole blood are agglutinated and then separated and removed in the case of using polybrene as a blood-agglutinating agent and the colloidal gold conjugates as a detection reagent. To solve the problem, the present inventers reviewed a past reagent configuration itself from a completely different viewpoint rather than selecting type and amount of polyanions and, as a result of extensive study on each element, the inventers surprisingly found that aggregation of colloidal gold can be suppressed by using a certain buffer solution without using neutralization by polyanions.
    Type: Application
    Filed: December 19, 2017
    Publication date: September 20, 2018
    Applicant: SEKISUI MEDICAL CO., LTD.
    Inventors: Mayumi YOSHIDA, Mitsuaki YAMAMOTO, Shinya YOKOKAWA, Tomo SHIMIZU, Keigo KONO
  • Publication number: 20180267034
    Abstract: Some embodiments described herein relate to a substrate comprising a silane functionalized surface for reversibly immobilizing a biological molecule of interest, such as oligonucleotides, polynucleotides, or protein. Methods for immobilizing the biological molecule and the use in DNA sequencing and other diagnostic applications are also disclosed.
    Type: Application
    Filed: May 3, 2018
    Publication date: September 20, 2018
    Inventors: Xavier von Hatten, Wayne N. George, Alexandre Richez, Anne-Cecile Dingwall, Andrew A. Brown
  • Publication number: 20180267035
    Abstract: Some embodiments are directed to a process for the diagnosis of systemic lupus erythematosus (SLE) and/or of chronic lymphoid leukaemia (CLL) of a subject who may be suffering therefrom, comprising the in vitro detection of the expression of the fraction of the STIM1 protein located at the cell plasma membrane in a biological sample from human and mice. Some other embodiments are directed to a process for predicting the progression and/or monitoring the progression of CLL and/or of SLE, comprising the in vitro detection of the expression of the fraction of the STIM1 protein located at the cell plasma membrane.
    Type: Application
    Filed: February 26, 2016
    Publication date: September 20, 2018
    Inventors: Yves RENAUDINEAU, Olivier MIGNEN, Marjolaine DEBANT, Christelle LE DANTEC, Jacques Olivier PERS
  • Publication number: 20180267036
    Abstract: Some embodiments disclosed herein provide a plurality of compositions each comprising a protein binding reagent conjugated with an oligonucleotide. The oligonucleotide comprises a unique identifier for the protein binding reagent it is conjugated with, and the protein binding reagent is capable of specifically binding to a protein target. Further disclosed are methods and kits for quantitative analysis of a plurality of protein targets in a sample and for simultaneous quantitative analysis of protein and nucleic acid targets in a sample. Also disclosed herein are systems and methods for preparing a labeled biomolecule reagent, including a labeled biomolecule agent comprising a protein binding reagent conjugated with an oligonucleotide.
    Type: Application
    Filed: May 30, 2018
    Publication date: September 20, 2018
    Inventors: Christina Fan, Olaf Zoellner
  • Publication number: 20180267037
    Abstract: Some embodiments of the invention include a kit and a device for detecting activated bifidobacteria. Methods of making and using the kit and/or device are also described herein.
    Type: Application
    Filed: December 23, 2015
    Publication date: September 20, 2018
    Inventors: David KYLE, David MILLS, Carlito LEBRILLA
  • Publication number: 20180267038
    Abstract: Herein is provided a method that provides a patient, suspected of having Lyme disease, a kit that does not require specialized equipment and allows for easy self-collection of specimens. Methods provided herein, allow for the efficient culturing of Borrelia spirochetes, such as B. burgdorferi spirochetes after being exposed to an environment that is typically not suitable for Borrelia growth.
    Type: Application
    Filed: December 23, 2015
    Publication date: September 20, 2018
    Inventors: Marianne Middelveen, Raphael Stricker
  • Publication number: 20180267039
    Abstract: A rapid test for a qualitative and/or quantitative assay of antibodies present in body fluid against human papilloma viruses (HPV) includes mixing a specimen of body fluid with a reagent which essentially comprises a predetermined quantity of physiologically acting liquid and a predetermined quantity of at least one HPV-specific antigen. The mixture is fed to an analysis which utilizes a change that is at least one of measurable or perceivable by a user.
    Type: Application
    Filed: May 22, 2018
    Publication date: September 20, 2018
    Inventor: Ralf Hilfrich
  • Publication number: 20180267040
    Abstract: This invention provides an anti-REIC antibody that specifically recognizes a cancer-associated protein (REIC/Dkk-3) and enables monitoring of cancer treatment effects involving the use of the REIC/Dkk-3 gene or the REIC/Dkk-3 protein as a medicine. This invention also provides a method of diagnosis involving the use of such antibody.
    Type: Application
    Filed: September 27, 2016
    Publication date: September 20, 2018
    Applicants: National University Corporation Okayama University, Momotaro-Gene Inc.
    Inventors: Hiromi Kumon, Rie KINOSHITA, Junichiro FUTAMI
  • Publication number: 20180267041
    Abstract: This disclosure generally relates to a molecular classification of cancer and particularly to molecular markers for predicting response to cancer therapy, including cancer immune therapy, and methods of use thereof.
    Type: Application
    Filed: May 17, 2018
    Publication date: September 20, 2018
    Inventor: Susanne Wagner
  • Publication number: 20180267042
    Abstract: The present invention provides a method for diagnosing and determining prognosis of colorectal cancer in a subject by detecting suppressed expression of the VSTM2A gene, which in some cases is due to elevated methylation level in the genomic sequence of this gene. A kit and device useful for such a method are also provided. In addition, the present invention provides a method for treating colorectal cancer by increasing VSTM2A gene expression or activity.
    Type: Application
    Filed: April 5, 2017
    Publication date: September 20, 2018
    Inventors: Jun Yu, Joseph Jao Yiu Sung, Simon Siu Man Ng, Yujuan Dong
  • Publication number: 20180267043
    Abstract: A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to a subject having cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is a compound of Formula (I):
    Type: Application
    Filed: October 6, 2015
    Publication date: September 20, 2018
    Inventors: Antonia LOPEZ-GIRONA, Brian E. CATHERS, Gang LU, Pilgrim JACKSON, Hiroshi HANDA
  • Publication number: 20180267044
    Abstract: The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to LRG1 protein markers for use in the diagnosis, prognosis, and determination of treatment of prostate cancer.
    Type: Application
    Filed: January 5, 2016
    Publication date: September 20, 2018
    Inventors: Ian Mills, Ingrid Jenny Guldvik
  • Publication number: 20180267045
    Abstract: The present invention relates to: a composition for diagnosing pancreatic cancer, containing a preparation for measuring the expression level of a protein or a gene thereof, and capable of being used for determining whether there is a risk of pancreatic cancer; a kit; and a method for diagnosing pancreatic cancer by using the same. The present invention can significantly predict or identify the risk of pancreatic cancer or a precancerous lesion of pancreatic cancer, the early diagnosis thereof and the extent of diseases thereof by providing a diagnostic marker of pancreatic cancer, and can be utilized in the research of pancreatic cancer oncogenesis. In addition, the diagnostic method of the present invention can provide simple and early diagnosis of pancreatic cancer from the blood and the like in a non-invasive manner.
    Type: Application
    Filed: May 24, 2018
    Publication date: September 20, 2018
    Inventors: Yonghwan Choi, Junghyun Namkung, Sung Gon Yi, Sangjo Han, Jin-Young Jang, Taesung Park, Youngsoo Kim
  • Publication number: 20180267046
    Abstract: Disclosed is a method for identifying a subject at risk of developing a recurrent or metastatic cancer, comprising detecting PD-L1+ circulating tumor cells in a blood sample, a tissue fluid sample or a specimen of the subject. Also disclosed is method for treating a cancer comprising identifying a subject having one ore more PD-L1+ circulating tumor cells by detecting PD-L1+ circulating tumor cells in a blood sample, a tissue fluid sample or a specimen of the subject, and administering a treatment to the subject.
    Type: Application
    Filed: March 13, 2018
    Publication date: September 20, 2018
    Applicant: MiCareo Taiwan Co., Ltd.
    Inventors: Ju-Yu Tseng, Yen-Ru Chen, Chia-Ying Lee, Li-Fan Wu, Shin-Hang Wang, Jui-Lin Chen, Chwen-Cheng Chen
  • Publication number: 20180267047
    Abstract: The present invention relates to a method for diagnosis of a cancer, comprising the steps of (i) determining the level of antibodies against vascular endothelial growth factor (VEGF) in a sample from a subject to be diagnosed, (ii) comparing the determined level in the sample to a control level derived from subjects without cancer; wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative for cancer in the subject. Furthermore, the invention relates to method of predicting response and outcome of a treatment of a cancer with an angiogenesis inhibitor.
    Type: Application
    Filed: February 3, 2015
    Publication date: September 20, 2018
    Inventor: Harald HEIDECKE
  • Publication number: 20180267048
    Abstract: A method (e.g. high resolution melting analysis) of determining of the presence or absence of a target nucleic acid in a sample, e.g. a biological sample, the method comprising steps of:?(a) contacting the sample with a composition comprising?(i) a quaternary ammonium compound, e.g. 3-(trimethoxysilyl) propyl-dimethyl octadecyl ammonium chloride (3-TPAC) or a precursor thereof, in order to release the nucleic acids from said sample; and?(b) contacting the sample with a probe which is capable of inter-acting with the nucleic acid sequence; and?(c) observing and/or measuring a property of the sample, e.g. fluorescence from a dsDNA binding dye.
    Type: Application
    Filed: July 28, 2016
    Publication date: September 20, 2018
    Inventors: Jan Rogers, Paul Reeves, Carlos Toro Rueda
  • Publication number: 20180267049
    Abstract: A method for analyzing or detecting methimazole (“MTZ”) comprising contacting a sample suspected of containing MTZ with the dendrimer-stabilized silver nanoparticles and performing surface-enhanced Raman scattering (SERS). Graphene-dendrimer-stabilized silver nanoparticles (G-D-Ag).
    Type: Application
    Filed: March 13, 2018
    Publication date: September 20, 2018
    Applicant: King Fahd University of Petroleum and Minerals
    Inventors: Tawfik A. SALEH, Mutasem M. AL-SHALAFEH, Abdulaziz A. AL-SAADI
  • Publication number: 20180267050
    Abstract: The present invention relates to a kit for radiolabelling a targeting agent with gallium-68. The present invention also relates to the use of said kit for radiolabelling a targeting agent, a method for radiolabelling a targeting agent with gallium-68 using said kit, said kit and a method of preparation.
    Type: Application
    Filed: May 17, 2018
    Publication date: September 20, 2018
    Applicant: ANMI S.A.
    Inventors: Ludovic Wouters, Geoffroy Kaisin, André Luxen, Marc Léonard, Samuel Voccia
  • Publication number: 20180267051
    Abstract: A method for screening compounds for their ability to interact with transmembrane proteins is provided. Also provided is a method for determining whether proteins such as transmembrane proteins are able to oligomerise.
    Type: Application
    Filed: March 14, 2018
    Publication date: September 20, 2018
    Inventors: Brian F. O'Dowd, Susan R. George
  • Publication number: 20180267052
    Abstract: An object of the present invention is to provide a method for efficiently identifying a polyubiquitinated substrate which is generally not easily identified. The method for identifying a polyubiquitinated substrate includes (1) a step of expressing a trypsin-resistant polyubiquitin chain-binding protein and a ubiquitin ligase in a cell, (2) a step of isolating a complex that contains the trypsin-resistant polyubiquitin chain-binding protein from the cell having undergone the step (1), (3) a step of subjecting the complex isolated by the step (2) to trypsin digestion, and (4) a step of identifying a peptide that has a ubiquitination site from a digested material obtained by the step (3).
    Type: Application
    Filed: November 13, 2014
    Publication date: September 20, 2018
    Inventors: Yukiko Yoshida, Yasushi Saeki, Hikaru Tsuchiya, Arisa Murakami, Keiji Tanaka
  • Publication number: 20180267053
    Abstract: Disclosed are systems and methods for developing diagnostic tests (e.g., detection, screening, monitoring, and prognostic tests) based on biomarker information from legacy clinical sample sets, for which only small sample volumes (e.g., about 0.05 to about 1.0 mL or less per sample) are typically available. For example, biomarkers (e.g., about 10, 50, 100, 150, 200, 300, or more) may be detected in the clinical samples through the use of single molecule detection and each biomarker may be detected in an assay that includes about 1 or less of a legacy clinical sample.
    Type: Application
    Filed: March 12, 2018
    Publication date: September 20, 2018
    Inventors: Michael S. Urdea, Michael P. McKenna
  • Publication number: 20180267054
    Abstract: Flow apparatuses comprising a separation channel, a downstream flow separator, a detection zone, an observation zone, and a waste channel. The separation channel has first and second flows in contact and allows lateral movement of components between contacting first and second flows. The downstream flow separator is in communication with the separation channel and diverts a part of the first fluid flow, the second fluid flow, or both, from the separation channel. The detection zone comprises a detection channel downstream of and in communication with the flow separator and configured to receive a plurality of diverted flows from the flow separator and a label channel configured to label the diverted flows from the flow separator. The observation zone is configured to record an analytical signal indicative of the quantity and the electrical properties of the component. The waste channel is at the downstream end of the observation zone.
    Type: Application
    Filed: March 15, 2018
    Publication date: September 20, 2018
    Applicant: Cambridge Enterprise Limited
    Inventors: Emma Yates, Christopher Dobson, Therese Herling, Tuomas Knowles
  • Publication number: 20180267055
    Abstract: The present invention provides a cell-based assay for identifying and/or quantifying anti-CD3 homodimers in a composition comprising a T cell-dependent Bispecific antibody (TDB). In some aspects, the invention T cells comprising a T cell activation responsive reporter are contacted with the TDB to detect the presence of anti-CD3 homodimers. Compositions of reporter T cells and kits are also contemplated.
    Type: Application
    Filed: November 28, 2017
    Publication date: September 20, 2018
    Applicant: Genentech, Inc.
    Inventor: Kendall CAREY
  • Publication number: 20180267056
    Abstract: The present invention provides compositions and methods that can be used to determine a peptide signature for an antibody repertoire in a sample comprising multiple antibodies. The method can be used to characterize a phenotype in a sample, such as providing a diagnosis, prognosis or theranosis of a medical condition.
    Type: Application
    Filed: May 29, 2018
    Publication date: September 20, 2018
    Inventors: Patrick Sean Daugherty, Kathryn Vinaya Louise Kamath, Jack Ryan Reifert
  • Publication number: 20180267057
    Abstract: This document relates to methods for identifying one or more immunoglobulin free light chains in a sample using mass spectrometry. For example, this document relates to a method for identifying one or more immunoglobulin free light chains in a sample that includes (a) providing a sample; (b) subjecting the sample to a mass spectrometry technique to obtain a mass spectrum of the sample; and (c) identifying the presence of the one or more immunoglobulin free light chains.
    Type: Application
    Filed: September 26, 2016
    Publication date: September 20, 2018
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: David R. Barnidge, David L. Murray
  • Publication number: 20180267058
    Abstract: The invention relates to a method of predicting therapeutic responses to TNF blockers before anti-TNF therapy comprising analyzing immune parameters to selected stimuli in patients before therapy and its use for anti-TNF therapy. The invention relates also to a method of determining a predictive biomarker of response to anti-TNF therapy and to the use of the predictive biomarker obtained by the method.
    Type: Application
    Filed: September 27, 2016
    Publication date: September 20, 2018
    Inventors: LARS ROGGE, SILVIA MENEGATTI, MAXIME DOUGADOS, ELISABETTA BIANCHI
  • Publication number: 20180267059
    Abstract: The invention features compositions and methods treating or preventing for age-related insulin resistance, type 2 diabetes and related disorders. The method involves depleting fTreg cells with an anti-ST2 antibody to decrease age-related fTreg accumulation and restore insulin sensitivity, thereby treating age-related insulin resistance, type 2 diabetes and related disorders.
    Type: Application
    Filed: January 12, 2016
    Publication date: September 20, 2018
    Applicant: SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: SAGAR P. BAPAT, YE ZHENG, RONALD EVANS, MICHAEL DOWNES, ANNETTE R. ATKINS, RUTH T. YU
  • Publication number: 20180267060
    Abstract: A method of bioassay for the quantification of peptide fragments elevated in lung diseases such as COPD, SCC, or IPF, comprising a neo-epitope formed at a cleavage site by cleavage in vivo of elastin by a proteinase by contacting a sample with an antibody having specific binding affinity for a the neo-epitope amino acid sequence and determining the level of binding, where the antibody binds one of the following terminal sequences: ...FGPGVV ...VPGLGV IKAPKL... and antibodies and immunoassay kits for use in such methods.
    Type: Application
    Filed: May 31, 2018
    Publication date: September 20, 2018
    Applicant: Nordic Bioscience A/S
    Inventors: Jacob Hull Kristensen, Diana Julie Oersnes-Leeming, Morten Darsdal
  • Publication number: 20180267061
    Abstract: The present invention provides methods for determining bone growth velocity comprising: (a) measuring an amount of a collagen X marker in a sample obtained from a subject in need thereof; and (b) comparing the amount of collagen X marker measured in step (a) with a collagen X marker standard curve, wherein the amount of collagen X marker is measured using at least two reagents. In an embodiment, there is at least one capture reagent and at least one detection reagent. In a preferred embodiment for measuring CXM, the capture reagent is the aptamer SOMA1 and the detection reagent is the monoclonal antibody mAb X34. The present invention further provides methods for treating diseases, disorders or conditions comprising receiving an identification of an amount of CXM in a sample, wherein the amount of CXM has been identified using a combination of SOMA1 and mAb X34 as CXM-binding reagents, and administering a treatment in light of the amount of CXM in the sample.
    Type: Application
    Filed: March 8, 2018
    Publication date: September 20, 2018
    Inventors: William A. Horton, Gregory P. Lunstrum, Ryan F. Coghlan, Jon A. Oberdorf
  • Publication number: 20180267062
    Abstract: The invention provides a method for determining the efficacy of compositions used to treat articular joint conditions in mammals. The method includes measuring the change in levels of one or more cartilage degradation biomarkers in a mammal from before exercise and after exercise, then administering a composition used to treat articular joint conditions to the mammal, and measuring the change in levels of one or more cartilage degradation biomarkers in the mammal from before exercise and after exercise.
    Type: Application
    Filed: May 22, 2018
    Publication date: September 20, 2018
    Inventor: Kevin J. Ruff
  • Publication number: 20180267063
    Abstract: The present invention provides methods for identifying biomarkers of disease capable of affecting cognitive function. The biomarkers identified by the methods of the prevention may be used for predicting whether a mammal will develop a disease capable of affecting cognitive function. More specifically, the present invention relates to the identification of biomarkers predictive of neurological diseases in a mammal and the use of these biomarkers in the diagnosis, differential diagnosis, and/or prognosis of the neurological disease. The methods and systems provided enable an assessment and theoretical prediction of neocortical amyloid loading based on the measurement of biomarkers that will provide an indication of whether a mammal is likely to develop a neurological disease.
    Type: Application
    Filed: January 25, 2018
    Publication date: September 20, 2018
    Applicants: CRC for Mental Health Ltd, Montana State University
    Inventors: Blaine Roberts, Edward A. Dratz, Scott Laffoon
  • Publication number: 20180267064
    Abstract: This invention provides for an improved method for differentially diagnosing ACTH-dependent Cushing's syndrome. Current practice for differentially diagnosing ectopic ACTH syndrome and Cushing's Disease measures relative ACTH concentrations from the inferior petrosal venous sinus compared to fluid obtained from a periphery venous sample. This is performed before and after administration of exogenous corticotropin releasing factor, or after administration of metyrapone. This invention uses glucocorticoid receptor antagonists to induce release of endogenous CRH which stimulates ACTH to increase in patients with ectopic ACTH syndrome but not in those with Cushing's Disease.
    Type: Application
    Filed: May 23, 2018
    Publication date: September 20, 2018
    Inventor: Andreas G. Moraitis
  • Publication number: 20180267065
    Abstract: Described herein are methods for measuring analytes, wherein a portion of the analyte in a sample is bound by a binding protein. In some embodiments, the methods relate to measuring vitamin D or metabolites thereof, e.g., vitamin D in samples also comprising a vitamin D binding protein.
    Type: Application
    Filed: March 15, 2018
    Publication date: September 20, 2018
    Applicant: Trustees of Boston University
    Inventor: Michael Francis Holick
  • Publication number: 20180267066
    Abstract: Lipid biomarkers for early detection of production-related metabolic disease in cattle are disclosed. The biomarkers are obtained from colostrum or milk. Methods for using and analyzing such lipid biomarkers, and methods for managing and treating dairy cattle are disclosed.
    Type: Application
    Filed: September 28, 2016
    Publication date: September 20, 2018
    Applicant: Brigham Young University
    Inventors: Beverly L. ROEDER, Steven William GRAVES
  • Publication number: 20180267067
    Abstract: The presently disclosed subject matter provides methods for quantifying levels of glutamine antagonists, such as 6-diazo-5-oxo-L-norleucine (DON), including such glutamine antagonists resulting from in vivo conversion of ester prodrugs of such glutamine antagonists, in a biological sample.
    Type: Application
    Filed: January 11, 2016
    Publication date: September 20, 2018
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: BARBARA S. SLUSHER, JESSE ALT, CAMILO ROJAS